Palisade Bio, Inc.
PALI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001357459
In the last 90 days, Palisade Bio, Inc. insiders filed 3 open-market purchases and 2 sales; 124 institutions reported holding it in 13F filings for Q2 2026, worth $362.4M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Palisade Bio, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 8
- −8 vs. Q1 2024
- Shares held
- 65.8K
- +1.43K (+2.2%) vs. Q1 2024Converted for a 1-for-15 split
- Total value
- $297.7K
- −$87.0K (−22.6%) vs. Q1 2024
- New holders
- 2
- 2 more added
- Sold out
- 10
- 2 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PALI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 124 | $362.4M |
| Q1 2026 | 96 | $261.7M |
| Q4 2025 | 86 | $319.4M |
| Q3 2025 | 12 | $102.8K |
| Q2 2025 | 11 | $57.5K |
| Q1 2025 | 13 | $200.9K |
| Q4 2024 | 10 | $387.7K |
| Q3 2024 | 9 | $347.4K |
| Q2 2024 | 8 | $297.7K |
| Q1 2024 | 16 | $384.6K |
| Q4 2023 | 16 | $158.3K |
| Q3 2023 | 13 | $86.6K |
| Q2 2023 | 11 | $228.7K |
| Q1 2023 | 9 | $29.8K |
| Q4 2022 | 12 | $648.0K |
| Q3 2022 | 33 | $842.0K |
| Q2 2022 | 26 | $395.0K |
| Q1 2022 | 25 | $930.0K |
| Q4 2021 | 28 | $1.70M |
| Q3 2021 | 22 | $2.03M |
| Q2 2021 | 23 | $10.1M |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Palisade Bio, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Marex Group plc | 35,759 | $162.3K | 0.00% | +33,375+1,400.0% | AddedConverted for a 1-for-15 split |
| Armistice Capital, LLC | 27,858 | $125.4K | 0.00% | −20,142−42.0% | ReducedConverted for a 1-for-15 split |
| UBS Group AG | 1,216 | $5.47K | 0.00% | +1,068+719.8% | AddedConverted for a 1-for-15 split |
| Tower Research Capital LLC (TRC) | 738 | $3.32K | 0.00% | +738 | New |
| Morgan Stanley | 140 | $630 | 0.00% | 00.0% | UnchangedConverted for a 1-for-15 split |
| Federation des caisses Desjardins du Quebec | 100 | $450 | 0.00% | 00.0% | UnchangedConverted for a 1-for-15 split |
| Wells Fargo & Company | 21 | $95 | 0.00% | −6−23.4% | ReducedConverted for a 1-for-15 split |
| Bank of America Corp | 5 | $22 | 0.00% | +5 | New |
| Vanguard Group Inc | 0 | $0 | 0.00% | −4,537−100.0% | Sold outConverted for a 1-for-15 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −2,297−100.0% | Sold outConverted for a 1-for-15 split |
| HRT Financial LP | 0 | $0 | 0.00% | −2,155−100.0% | Sold outConverted for a 1-for-15 split |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −1,881−100.0% | Sold outConverted for a 1-for-15 split |
| State Street Corp | 0 | $0 | 0.00% | −1,498−100.0% | Sold outConverted for a 1-for-15 split |
| Millennium Management LLC | 0 | $0 | 0.00% | −1,213−100.0% | Sold outConverted for a 1-for-15 split |
| Orion Capital Management LLC | 0 | $0 | 0.00% | −20−100.0% | Sold outConverted for a 1-for-15 split |
| BFSG, LLC | 0 | $0 | 0.00% | −3−100.0% | Sold outConverted for a 1-for-15 split |
| BlackRock Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-15 split |
| FMR LLC | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-15 split |